The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
Standard
The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. / Chilcott, James B; Holmes, Michael W; Walters, Stephen; Akehurst, Ronald L; Nashan, Björn.
in: TRANSPL INT, Jahrgang 15, Nr. 9-10, 9-10, 2002, S. 486-493.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
AU - Chilcott, James B
AU - Holmes, Michael W
AU - Walters, Stephen
AU - Akehurst, Ronald L
AU - Nashan, Björn
PY - 2002
Y1 - 2002
N2 - An economic evaluation was undertaken alongside a multicentre international trial of basiliximab. Resource usage within the trial was assessed, and the cost implications of using basiliximab evaluated. Recipients of a primary cadaveric kidney transplant were recruited into a double-blind trial and received either placebo ( n=186) or basiliximab ( n=190). Clinical outcomes and resource usage were monitored in the 12 months following transplantation. Local unit costs were obtained, and global analysis was undertaken using health sector purchasing-power parity rates. No statistically significant differences were found in the mean cost of treatment per patient. The mean cost of treatment was US$47,940 for basiliximab patients and US$46,280 for placebo patients, a mean difference of US$1,660 (95% confidence interval (CI): -US$4,150, US$7,360; P=0.58). Basiliximab produces clinical benefit in terms of preventing episodes of acute rejection, whilst the difference in the total resource usage and cost of treatment is not statistically significant.
AB - An economic evaluation was undertaken alongside a multicentre international trial of basiliximab. Resource usage within the trial was assessed, and the cost implications of using basiliximab evaluated. Recipients of a primary cadaveric kidney transplant were recruited into a double-blind trial and received either placebo ( n=186) or basiliximab ( n=190). Clinical outcomes and resource usage were monitored in the 12 months following transplantation. Local unit costs were obtained, and global analysis was undertaken using health sector purchasing-power parity rates. No statistically significant differences were found in the mean cost of treatment per patient. The mean cost of treatment was US$47,940 for basiliximab patients and US$46,280 for placebo patients, a mean difference of US$1,660 (95% confidence interval (CI): -US$4,150, US$7,360; P=0.58). Basiliximab produces clinical benefit in terms of preventing episodes of acute rejection, whilst the difference in the total resource usage and cost of treatment is not statistically significant.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 486
EP - 493
JO - TRANSPL INT
JF - TRANSPL INT
SN - 0934-0874
IS - 9-10
M1 - 9-10
ER -
